Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag + Dexamethasone in Newly Diagnosed ITP
NCT04346654Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eltrombopag in immune thrombocytopenia (ITP) (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Patients With Sustained Response Off Treatment at 52 Weeks. Started Oct 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04346654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346654.